JP2024533700A5 - - Google Patents
Info
- Publication number
- JP2024533700A5 JP2024533700A5 JP2024518606A JP2024518606A JP2024533700A5 JP 2024533700 A5 JP2024533700 A5 JP 2024533700A5 JP 2024518606 A JP2024518606 A JP 2024518606A JP 2024518606 A JP2024518606 A JP 2024518606A JP 2024533700 A5 JP2024533700 A5 JP 2024533700A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- alopecia
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163247672P | 2021-09-23 | 2021-09-23 | |
| US63/247,672 | 2021-09-23 | ||
| PCT/US2022/044346 WO2023049241A1 (en) | 2021-09-23 | 2022-09-22 | Methods of treating hair-loss disorders with tyk2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533700A JP2024533700A (ja) | 2024-09-12 |
| JP2024533700A5 true JP2024533700A5 (https=) | 2025-10-02 |
Family
ID=83899658
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024518606A Pending JP2024533700A (ja) | 2021-09-23 | 2022-09-22 | チロシンキナーゼ２（ｔｙｋ２）阻害剤による脱毛症の治療方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240390372A1 (https=) |
| EP (1) | EP4404930A1 (https=) |
| JP (1) | JP2024533700A (https=) |
| KR (1) | KR20240065283A (https=) |
| CN (2) | CN118251222A (https=) |
| AU (1) | AU2022350509A1 (https=) |
| CA (1) | CA3232812A1 (https=) |
| IL (1) | IL311624A (https=) |
| MX (1) | MX2024003510A (https=) |
| WO (1) | WO2023049241A1 (https=) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3495358T (lt) | 2012-11-08 | 2022-05-25 | Bristol-Myers Squibb Company | Amidais pakeisti heterocikliniai junginiai, naudingi kaip il-12, il-23 ir (arba) ifn alfa atsako moduliatoriai |
| TWI582077B (zh) * | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| TW202515876A (zh) * | 2017-03-08 | 2025-04-16 | 日商武田藥品工業股份有限公司 | Tyk2抑制劑及其用途 |
| JP7113023B2 (ja) * | 2017-03-30 | 2022-08-04 | ブリストル－マイヤーズ スクイブ カンパニー | ６－（シクロプロパンアミド）－４－（（２－メトキシ－３－（１－メチル－１ｈ－１，２，４－トリアゾール－３－イル）フェニル）アミノ）－ｎ－（メチル－ｄ３）ピリダジン－３－カルボキシアミドの製造方法 |
| KR102848769B1 (ko) | 2018-05-31 | 2025-08-20 | 브리스톨-마이어스 스큅 컴퍼니 | 6-(시클로프로판카르복스아미도)-4-((2-메톡시-3-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)아미노)-n-(메틸-d3) 피리다진-3-카르복스아미드의 결정질 형태 |
| US20230093099A1 (en) * | 2019-04-02 | 2023-03-23 | Cullgen (Shanghai), Inc. | Compounds and methods of treating cancers |
| US11357775B2 (en) * | 2019-04-30 | 2022-06-14 | Celgene Corporation | Combination therapies comprising apremilast and Tyk2 inhibitors |
| SG11202112043PA (en) * | 2019-04-30 | 2021-11-29 | Celgene Corp | Combination therapies comprising apremilast and tyk2 inhibitors |
| US12570637B2 (en) | 2019-06-12 | 2026-03-10 | Bristol-Myers Squibb Company | Crystalline salt forms 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyld3) pyridazine-3-carboxamide |
| JP7812785B2 (ja) | 2019-09-18 | 2026-02-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｙｋ２阻害薬の剤形 |
| AU2021205465A1 (en) * | 2020-01-06 | 2022-07-14 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CN111704617B (zh) * | 2020-06-15 | 2022-08-23 | 嘉兴特科罗生物科技有限公司 | 一种小分子化合物 |
| CN112142675B (zh) * | 2020-10-09 | 2021-11-30 | 嘉兴特科罗生物科技有限公司 | 一种作为jak激酶抑制剂的小分子化合物及其用途 |
-
2022
- 2022-09-22 EP EP22792963.5A patent/EP4404930A1/en active Pending
- 2022-09-22 JP JP2024518606A patent/JP2024533700A/ja active Pending
- 2022-09-22 CN CN202280075809.3A patent/CN118251222A/zh active Pending
- 2022-09-22 KR KR1020247012854A patent/KR20240065283A/ko active Pending
- 2022-09-22 AU AU2022350509A patent/AU2022350509A1/en active Pending
- 2022-09-22 CN CN202411332236.5A patent/CN119345364A/zh active Pending
- 2022-09-22 CA CA3232812A patent/CA3232812A1/en active Pending
- 2022-09-22 MX MX2024003510A patent/MX2024003510A/es unknown
- 2022-09-22 US US18/694,424 patent/US20240390372A1/en active Pending
- 2022-09-22 WO PCT/US2022/044346 patent/WO2023049241A1/en not_active Ceased
- 2022-09-22 IL IL311624A patent/IL311624A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6931019B2 (ja) | 多発性硬化症を処置するためのｓ１ｐ受容体モジュレーター | |
| JP2025186241A5 (https=) | ||
| ES2285733T3 (es) | Agente antipruritico. | |
| JP2024133474A5 (https=) | ||
| JP2007533686A5 (https=) | ||
| CN104023715B (zh) | 激酶抑制剂的副作用降低剂 | |
| JP2005509662A5 (https=) | ||
| JP2021530554A5 (https=) | ||
| JP2024531188A5 (https=) | ||
| JP2024507810A5 (https=) | ||
| JP2015528501A5 (https=) | ||
| AU2021227007A1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3S)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7H-benzo[7]annulene-2-carboxylic acid | |
| MX2024010637A (es) | Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP7734742B2 (ja) | 癌併用療法におけるｄｈｏｄｈ阻害剤化合物の利用 | |
| CL2024003616A1 (es) | Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| JP2023549849A5 (https=) | ||
| BRPI0716214A2 (pt) | Composições farmacêuticas para o tratamento de infecções fúngicas. | |
| JP2023553253A5 (https=) | ||
| JP2025503015A5 (https=) | ||
| JP2024533700A5 (https=) | ||
| JP2022177119A5 (https=) | ||
| ES2309357T3 (es) | Nueva combinacion sinergica que comprende roflumilast y formoterol. | |
| CN110290788A (zh) | 氨基甲酸酯化合物用于预防、缓解或治疗双相障碍的用途 | |
| BR112018005771B1 (pt) | Uso de um composto | |
| JP2024545496A5 (https=) |